Because of the biological diversity of KRAS-mutant NSCLC [30,31] and the clinical unavailability of direct inhibitors of KRAS, a treatment strategy for patients with KRAS-mutated NSCLC has not yet been established. This evidence concerns the gene KRAS and non-small cell lung carcinoma.